JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wakasugi, S.
Right arrow Articles by Hasegawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wakasugi, S.
Right arrow Articles by Hasegawa, Y.
Journal of Nuclear Medicine Vol. 43 No. 5 596-602
© 2002 by Society of Nuclear Medicine


Clinical Investigations

Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases

Shigetoshi Wakasugi, MD1, Atushi Noguti, BS1, Toshizou Katuda, PhD1, Terumi Hashizume1 and Yoshihisa Hasegawa, MD1

1 Department of Nuclear Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan

In this study, we evaluated the potential of 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) for detecting bone metastases in comparison with a conventional bone tracer. Methods: 99mTc-MIBI and 99mTc-hydroxymethylene diphosphonate (HMDP) scans were obtained from 99 patients with proven malignant diseases and suspected bone metastases. We compared 373 lesions that showed abnormal uptake on 99mTc-MIBI scans or 99mTc-HMDP scans (or both). Results: Bone metastases were confirmed in 334 of 373 lesions. Thirty-nine lesions on 99mTc-HMDP scans had false-positive findings, but only 2 of these lesions had false-positive findings on 99mTc-MIBI scans. 99mTc-MIBI and 99mTc-HMDP scans were equivalent in 168 of 334 lesions (50.3%). 99mTc-MIBI scans correctly detected more lesions than 99mTc-HMDP scans: 284 lesions (85.0%) versus 218 lesions (65.3%) (P < 0.005), respectively. 99mTc-MIBI scans showed a markedly higher sensitivity for detecting metastases in the femur and humerus compared with 99mTc-HMDP scans: 97 of 98 lesions (99.0%) versus 35 of 98 lesions (35.7%) (P < 0.005) and 21 of 22 lesions (95.5%) versus 11 of 22 lesions (50.0%) (P < 0.005), respectively. 99mTc-HMDP scans of 17 patients showed no abnormal images. However, 99mTc-MIBI scans correctly detected bone metastases, and subsequent development of multiple lesions was observed on follow-up 99mTc-HMDP scans of 15 patients. 99mTc-MIBI scans were superior to 99mTc-HMDP scans in the detection of metastases attributed to breast cancer, multiple myeloma, and hepatoma. On the contrary, 99mTc-MIBI scans were less sensitive than 99mTc-HMDP scans for detecting bone metastases attributed to prostate cancer in the other skeletal sites except for femur and humerus. Conclusion: 99mTc-MIBI scans have better sensitivity for detecting bone metastases and provide more specific complementary findings than conventional bone scans. 99mTc-MIBI accumulation attributed to bone marrow metastases may occur at an early stage, before the bone remodeling process in the surrounding bone can be detected on conventional bone scans.

Key Words: bone marrow metastases • bone metastases • 99mTc-MIBI scan • 99mTc-HMDP scan




This article has been cited by other articles:


Home page
JNMHome page
G. Mariani, M. Filocamo, F. Giona, G. Villa, A. Amendola, P. Erba, F. Buffoni, F. Copello, A. Pierini, F. Minichilli, et al.
Severity of Bone Marrow Involvement in Patients with Gaucher's Disease Evaluated by Scintigraphy with 99mTc-Sestamibi
J. Nucl. Med., August 1, 2003; 44(8): 1253 - 1262.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.